Urocortin 2 Infusion in Healthy Humans

• Published in: Journal of the American College of Cardiology Vol. 49; no. 4; pp. 461 - 471
• Main Authors: Davis, Mark E., MBChB, Pemberton, Christopher J., PhD, Yandle, Timothy G., PhD, Fisher, Steve F., DMLT, Lainchbury, John G., MD, Frampton, Christopher M., PhD, Rademaker, Miriam T., PhD, Richards, A. Mark, MD, PhD
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 2007
• Subjects: Cardiovascular; Internal Medicine; A; UCN; urocortin; E; transmitral diastolic flow velocity with atrial contraction; ACTH; corticotrophin-releasing factor; Em; Am; adrenocorticotropic hormone; SVR; early diastolic myocardial velocity; CRF; transmitral early diastolic flow velocity; diastolic myocardial velocity during atrial contraction; systemic vascular resistance
• ISSN: 0735-1097; 1558-3597
• DOI: 10.1016/j.jacc.2006.09.035

Urocortin 2 Infusion in Healthy Humans: Hemodynamic, Neurohormonal, and Renal Responses Mark E. Davis, Christopher J. Pemberton, Timothy G. Yandle, Steve F. Fisher, John G. Lainchbury, Christopher M. Frampton, Miriam T. Rademaker, A. Mark Richards The urocortins are vasoactive and cardioprotective peptides belonging to the corticotrophin-releasing factor peptide family. We infused urocortin 2 (UCN 2), for the first time in human subjects, to assess its effect on hemodynamics, cardiovascular hormones, and renal function. In 8 healthy men, infusions of 25 μg and 100μg of UCN 2 dose-dependently increased cardiac output, heart rate, and left ventricular ejection fraction while decreasing systemic vascular resistance. Plasma renin, angiotensin II, and norepinephrine were increased at the higher dose. Subtle decreases in urine volume and natriuresis were observed. These results warrant further investigation of UCN 2’s role in circulatory regulation and potential therapeutic applications in heart disease.